Iron sucrose: assessing the similarity between the originator drug and its intended copies

Annals of the New York Academy of Sciences

Volumn 1407, Issue 1, 2017, Pages 63-74

  Di Francesco, Tiziana ^a   Philipp, Erik ^b   Borchard, Gerrit ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Vifor International Inc   (Switzerland)

Author keywords

dynamic light scattering; iron sucrose; iron sucrose similars; labile iron; physicochemical characterization; zeta potential

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; FERROZINE; IRON SACCHARATE; SEN TIE NENG; TIAN XING; UNCLASSIFIED DRUG; WEI XIN KANG; FERRIC ION; SACCHARIC ACID;

ARTICLE; ATOMIC FORCE MICROSCOPY; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MARKETING; DRUG QUALITY; DRUG STABILITY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PROSPECTIVE STUDY; ZETA POTENTIAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG APPROVAL; IRON DEFICIENCY ANEMIA; MEDICINAL CHEMISTRY; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; THERAPEUTIC EQUIVALENCE;

ANEMIA, IRON-DEFICIENCY; BIOSIMILAR PHARMACEUTICALS; CHEMICAL PHENOMENA; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; FERRIC COMPOUNDS; GLUCARIC ACID; HUMANS; PARTICLE SIZE; TECHNOLOGY, PHARMACEUTICAL; THERAPEUTIC EQUIVALENCY;

EID: 85039843949     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13517     Document Type: Article

References (51)

1. Camaschella, C. 2015. Iron-deficiency anemia. N. Engl. J. Med. 372: 1832–1843.
2. Andrews, N.C. 1999. Disorders of iron metabolism. N. Engl. J. Med. 341: 1986–1995.
3. Macdougall, I.C. 1999. Strategies for iron supplementation: oral versus intravenous. Kidney Int. Suppl. 69: S61–S66.
4. Macdougall, I.C. 2009. Evolution of iv iron compounds over the last century. J. Ren. Care 35: 8–13.
5. Maslovsky, I. 2005. Intravenous iron in a primary-care clinic. Am. J. Hematol. 78: 261–264.
6. Toblli, J.E., G. Cao, L. Oliveri, et al. 2009. Differences between the original iron sucrose complex Venofer and the iron sucrose similar Generis, and potential implications. Port. J. Nephrol. Hypert. 23: 53–63.
7. Geisser, P., M. Baer & E. Schaub. 1992. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 42: 1439–1452.
8. Auerbach, M. & H. Ballard. 2010. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am. Soc. Hematol. Educ. Program 2010: 338–347.
9. Heath, C.W., M.B. Strauss & W.B. Castle. 1932. Quantitative aspects of iron deficiency in hypochromic anemia: (The parenteral administration of iron). J. Clin. Invest. 11: 1293–1312.
10. Nissim, J.A. 1947. Intravenous administration of iron. Lancet 2: 49–51.
11. Nissim, J. & J.M. Robson. 1949. Preparation and standardisation of saccharated iron oxide for intravenous administration. Lancet 253: 686–689.
12. Singh, H., J. Reed, S. Noble, et al. 2006. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin. J. Am. Soc. Nephrol. 1: 475–482.
13. Del Vecchio, L., S. Longhi & F. Locatelli. 2016. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin. Kidney J. 9: 260–267.
14. Bailie, G.R., M. Larkina, D.A. Goodkin, et al. 2015. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 87: 162–168.
15. Bailie, G.R., C.A. Johnson & N.A. Mason. 2000. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am. J. Kid. Dis. 35: 1–12.
16. Goldberg, L.A. 2010. Iron similars. Hospital Pharmacy Europe. 48. http://www.hospitalpharmacyeurope.com/clinical-review-iron-deficiency/iron-sucrose-similars.
17. Chertow, G.M., P.D. Mason, O. Vaage-Nilsen, et al. 2006. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 21: 378–382.
18. Cancado, R.D. & M. Munoz. 2011. Intravenous iron therapy: how far have we come? Rev. Bras. Hematol. Hemoter. 33: 461–469.
19. Kudasheva, D.S., J. Lai, A. Ulman, et al. 2004. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J. Inorg. Biochem. 98: 1757–1769.
20. Dunne, S., B. Shannon, C. Dunne, et al. 2013. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol. Toxicol. 14: 1.
21. Rottembourg, J., A. Kadri, E. Leonard, et al. 2011. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant. 26: 3262–3267.
22. Agüera, M.L., A. Martin-Malo, M.A. Alvarez-Lara, et al. 2015. Efficiency of original versus generic intravenous iron formulations in patients on haemodialysis. PLoS One 10: e0135967.
23. Lee, E.S., B.R. Park, J.S. Kim, et al. 2013. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr. Med. Res. Opin. 29: 141–147.
24. Martin-Malo, A., A. Merino, J. Carracedo, et al. 2012. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 27: 2465–2471.
25. Stein, J., A. Dignass & K. Chow. 2012. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr. Med. Res. Opin. 28: 241–243.
26. Toblli, J.E., G. Cao & M. Angerosa. 2015. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator. Biometals 28: 279–292.
27. Crommelin, D.J.A., J.S.B. de Vlieger, V. Weinstein, et al. 2014. Different pharmaceutical products need similar terminology. AAPS J. 16: 11–14.
28. Borchard, G., B. Fluhmann & S. Muhlebach. 2012. Nanoparticle iron medicinal products—requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul. Toxicol. Pharmacol. 64: 324–328.
29. Hussaarts, L., S. Mühlebach, V.P. Shah, et al. 2017. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Ann. N.Y. Acad. Sci. 1407: 39–49.
30. Toblli, J.E., G. Cao, L. Oliveri, et al. 2009. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 59: 176–190.
31. Toblli, J.E., G. Cao, L. Oliveri, et al. 2012. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy Drug Targets 11: 66–78.
32. Mühlebach, S. & B. Flühmann. 2015. Iron carbohydrate complexes: characteristics and regulatory challenges. In Non-Biological Complex Drugs: The Science and The Regulatory Landscape. D.J.A. Crommelin & J.S.B. de Vlieger, Eds.: 149–170. Cham: Springer International Publishing.
33. Zheng, N., D.D. Sun, P. Zou, et al. 2017. Scientific and regulatory considerations for generic complex drug products containing nanomaterials. AAPS J. 19: 619–631.
34. Schellekens, H., E. Klinger, S. Muhlebach, et al. 2011. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol. 59: 176–183.
35. Borchard, G. 2016. Complexity in the making: non-biological complex drugs (NBCDs) and the pharmacopoeias. GaBI 5: 36–41.
36. Bawa, R., G.F. Audette & B.E. Reese. 2016. Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety, and Risk. CRC Press—Taylor & Francis Group.
37. EMA. 2015. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. Accessed February 1, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184922.pdf.
38. US Food and Drug Administration. 2016. GDUFA regulatory science priorities for fiscal year 2017. Accessed April 1, 2017. https://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrugUserFees/UCM526900.pdf.
39. Koralewski, M., M. Pochylski & J. Gierszewski. 2013. Magnetic properties of ferritin and akaganeite nanoparticles in aqueous suspension. J. Nanopart. Res. 15: 1–20.
40. U.S. Pharmacopeial Convention. 2016. Iron sucrose injection. Accessed April 1, 2017. http://www.uspnf.com/uspnf/pdf/download?usp=39&nf=34&s=2&q=usp39nf34s2_m42475.pdf&officialOn=December_1,2016&target=oldwindow&time=1491407451161.
41. Sigma Aldrich. 2016. Product information—iron assay kit MAK025. Accessed October 10, 2017. http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Bulletin/1/mak025bul.pdf.
42. Kaszuba, M., D. McKnight, M.T. Connah, et al. 2008. Measuring sub nanometre sizes using dynamic light scattering. J. Nanopart. Res. 10: 823–829.
43. Jahn, M.R., H.B. Andreasen, S. Futterer, et al. 2011. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78: 480–491.
44. Shekunov, B.Y., P. Chattopadhyay, H.H. Tong, et al. 2007. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm. Res. 24: 203–227.
45. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2005. Validation of analytical procedures: text and methodology Q2 (R1). Accessed January 1, 2017. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
46. The International Organization for Standardization. 2017. Particle size analysis—dynamic light scattering (DLS). Accessed Februaruy 1, 2017. https://www.iso.org/standard/65410.html.
47. Elford, P., J. Bouchard, L. Jaillet, et al. 2013. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose. J. Pharmacol. Toxicol. Methods 68: 374–383.
48. Breuer, W., C. Hershko & Z.I. Cabantchik. 2000. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23: 185–192.
49. Van Wyck, D.B. 2004. Labile iron: manifestations and clinical implications. J. Am. Soc. Nephrol. 15: S107–S111.
50. Garcic, A. 1979. A highly sensitive, simple determination of serum ion using chromazurol B. Clin. Chim. Acta 94: 115–117.
51. Tabacco, A., E. Moda, P. Tarli, et al. 1981. An improved, highly sensitive method for the determination of serum iron using chromazurol B. Clin. Chim. Acta 114: 287–290.